Finanzen von Aldeyra Therapeutics Inc (ALDX)ALDXAldeyra Therapeutics Inc

Evaluating the bottom line, Aldeyra Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -21.37%, provide a clear picture of how effectively ALDX converts its operational activities into shareholder value.

In the context of the broader market, ALDX competes directly with industry leaders such as IMMP and IRLA. With a market capitalization of $38.68M, it holds a leading position in the sector. When comparing efficiency, ALDX's gross margin of N/A stands against IMMP's 100.00% and IRLA's N/A. Such benchmarking helps identify whether Aldeyra Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Aldeyra has consistently reported negative net income, with the latest figures showing a net loss of $5,450,273 in Q2 2026. The forward P/E ratio is 0, indicating no earnings expected in the near future, and the gross profit has been negative in recent quarters, highlighting ongoing financial struggles.